{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:20:36Z","timestamp":1787811636878,"version":"build-2784847793"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>\u0391bstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Chronic hypoparathyroidism (HypoPT) is a rare endocrine disorder characterized by hypocalcemia and hyperphosphatemia, requiring lifelong treatment with activated vitamin-D and oral calcium supplements. Palopegteriparatide, a novel long-acting prodrug of PTH (1\u201334), has demonstrated efficacy in randomized controlled trials, but real-world data on its long-term effectiveness and safety remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of long-term palopegteriparatide therapy in a real-world cohort of patients with HypoPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Setting<\/jats:title>\n                    <jats:p>Multicenter prospective cohort study conducted in tertiary referral hospitals. The study is registered at ClinicalTrials.gov under the identifier NCT07299838.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Intervention<\/jats:title>\n                    <jats:p>Ninety-two adults with HypoPT (79 females, 13 males), previously treated with recombinant human PTH (1\u201384) or conventional therapy, initiated palopegteriparatide according to the National Hellenic Guidelines for the management of HypoPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients were treated for a median duration of 6.5 months (range 2\u201314), with significant improvements in biochemical control of calcium-phosphate metabolism. Albumin-adjusted calcium increased from 8.14 \u00b1 0.73 to 8.99 \u00b1 0.94\u2005mg\/dL, and magnesium from 1.79 \u00b1 0.17 to 1.96 \u00b1 0.17\u2005mg\/dL (both P &amp;lt; .001). Phosphate decreased from 4.74 \u00b1 0.97 to 4.02 \u00b1 0.63\u2005mg\/dL (P &amp;lt; .001), Ca \u00d7 P product from 38.27 \u00b1 6.92 to 36.04 \u00b1 6.55 mg2\/dL2 (P = .017), and 24-hour urinary calcium from 245.7 \u00b1 125.5 to 164.5 \u00b1 88.3\u2005mg\/24\u2005h (P &amp;lt; .001). Daily pill burden was markedly reduced, and 58% of patients achieved independence from calcium supplements and alfacalcidol after a median of 30 days. Adverse events were mostly mild and transient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real-world setting, palopegteriparatide effectively normalizes calcium\u2013phosphate homeostasis, reduces hypercalciuria, and substantially decreases reliance on conventional therapy, with a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag145","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:03:01Z","timestamp":1787810581000},"page":"372-383","source":"Crossref","is-referenced-by-count":0,"title":["Real-world data for effectiveness and safety of palopegteriparatide in patients with chronic hypoparathyroidism: the PaTH REAL study"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-3692","authenticated-orcid":false,"given":"Maria P","family":"Yavropoulou","sequence":"first","affiliation":[{"name":"Endocrinology Unit, First Department of Propaedeutic and Internal Medicine, Centre of Expertise for Rare Endocrine Diseases (C.E.R.E.D), European Reference Network on Rare Endocrine Conditions (Endo-ERN), National and Kapodistrian University of Athens , Athens, TK 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8301-324X","authenticated-orcid":false,"given":"Symeon","family":"Tournis","sequence":"additional","affiliation":[{"name":"Laboratory for Research of the Musculoskeletal System \u2018Th. Garofalidis\u2019, Medical School, National and Kapodistrian University of Athens, KAT General Hospital, Kifissia , Athens, TK 14561 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Eleni","family":"Chondrogianni","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, First Department of Propaedeutic and Internal Medicine, Centre of Expertise for Rare Endocrine Diseases (C.E.R.E.D), European Reference Network on Rare Endocrine Conditions (Endo-ERN), National and Kapodistrian University of Athens , Athens, TK 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimos","family":"Florakis","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, First Department of Propaedeutic and Internal Medicine, Centre of Expertise for Rare Endocrine Diseases (C.E.R.E.D), European Reference Network on Rare Endocrine Conditions (Endo-ERN), National and Kapodistrian University of Athens , Athens, TK 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Chrisoulidou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Theagenio Hospital , Thessaloniki, TK 54639 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotini","family":"Adamidou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, \u201cIppokratio\u201d General Hospital of Thessaloniki , Thessaloniki, TK 54642 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi","family":"Efstathiadou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, \u201cIppokratio\u201d General Hospital of Thessaloniki , Thessaloniki, TK 54642 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Giagourta","sequence":"additional","affiliation":[{"name":"Endocrinology Department and Diabetes Center, General Hospital of Athens , G.Gennimatas, Athens, TK 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Giannou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetological Center, Alexandra General Hospital of Athens , Athens, TK 11528 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Stratigou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, \u201cD. Ikkos\u201d, European Reference Network on Rare Endocrine Conditions, Endo-ERN, Evangelismos Hospital , Athens, TK 10676 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Markou","sequence":"additional","affiliation":[{"name":"Endocrinology Department and Diabetes Center, General Hospital of Athens , G.Gennimatas, Athens, TK 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Vasileiou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetological Center, Alexandra General Hospital of Athens , Athens, TK 11528 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Ntali","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, \u201cD. Ikkos\u201d, European Reference Network on Rare Endocrine Conditions, Endo-ERN, Evangelismos Hospital , Athens, TK 10676 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysanthi","family":"Balodimou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Theagenio Hospital , Thessaloniki, TK 54639 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kalogeris","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism\u2014Diabetes Center, Korgialenio-Benakio General Hospital , Hellenic Red Cross, Athens , TK 11526, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Evangelia","family":"Koloutsou","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, First Department of Propaedeutic and Internal Medicine, Centre of Expertise for Rare Endocrine Diseases (C.E.R.E.D), European Reference Network on Rare Endocrine Conditions (Endo-ERN), National and Kapodistrian University of Athens , Athens, TK 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital , Athens, TK 11525 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andromachi","family":"Vryonidou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism\u2014Diabetes Center, Korgialenio-Benakio General Hospital , Hellenic Red Cross, Athens , TK 11526, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-2297","authenticated-orcid":false,"given":"Eva","family":"Kassi","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, First Department of Propaedeutic and Internal Medicine, Centre of Expertise for Rare Endocrine Diseases (C.E.R.E.D), European Reference Network on Rare Endocrine Conditions (Endo-ERN), National and Kapodistrian University of Athens , Athens, TK 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"11","key":"2026082702025884900_lvag145-B1","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.eprac.2025.07.011","article-title":"Chronic hypoparathyroidism\u2014current and emerging therapies","volume":"31","author":"Khan","year":"2025","journal-title":"Endocr Pract"},{"issue":"12","key":"2026082702025884900_lvag145-B2","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/jbmr.4714","article-title":"Etiology and pathophysiology of hypoparathyroidism: a narrative review","volume":"37","author":"Pasieka","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026082702025884900_lvag145-B3","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/jbmr.2004","article-title":"Prevalence and incidence of hypoparathyroidism in the United States using a large claims database","volume":"28","author":"Powers","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2026082702025884900_lvag145-B4","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.70.AEP140","article-title":"Prevalence of hypoparathyroidism in the EU: a systematic review and meta-analysis","author":"Karpf","year":"2020","journal-title":"Endocr Abstr"},{"key":"2026082702025884900_lvag145-B5","article-title":"Diagnosis and management of hypoparathyroidism: recommendations of the working group of the bone section of the hellenic endocrine society","author":"Kassi","year":"2025","journal-title":"Hormones"},{"issue":"4","key":"2026082702025884900_lvag145-B6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1210\/endrev\/bnaf010","article-title":"Bone in parathyroid diseases revisited: evidence from epidemiological, surgical and new drug outcomes","volume":"46","author":"Roumpou","year":"2025","journal-title":"Endocr Rev"},{"issue":"11","key":"2026082702025884900_lvag145-B7","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jbmr.1979","article-title":"Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study","volume":"28","author":"Underbjerg","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026082702025884900_lvag145-B8","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/jbmr.3368","article-title":"Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study","volume":"33","author":"Underbjerg","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026082702025884900_lvag145-B9","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/jbmr\/zjaf061","article-title":"Increased risk of vertebral fractures and reduced risk of femur fractures in patients with chronic hypoparathyroidism: a nationwide cohort study in Sweden","volume":"40","author":"Bj\u00f6rnsdottir","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026082702025884900_lvag145-B10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/ejendo\/lvaf169","article-title":"Health-related quality of life in a cohort of 1070 patients with hypoparathyroidism","volume":"193","author":"Siggelkow","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026082702025884900_lvag145-B11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12020-023-03443-2","article-title":"Impairments in quality of life and predictors of symptom burden in patients with hypoparathyroidism: results from a population-based survey","volume":"82","author":"B\u00fcttner","year":"2023","journal-title":"Endocrine"},{"issue":"12","key":"2026082702025884900_lvag145-B12","doi-asserted-by":"publisher","first-page":"e4004","DOI":"10.1210\/clinem\/dgaf257","article-title":"Increased risk of cardiovascular diseases in patients with chronic hypoparathyroidism in Sweden","volume":"110","author":"Bj\u00f6rnsdottir","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026082702025884900_lvag145-B13","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults","volume":"35","author":"Karpf","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026082702025884900_lvag145-B14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2026082702025884900_lvag145-B15","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.99.OC2.2","article-title":"Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway trial","author":"Schwarz","year":"2024","journal-title":"Endocr Abstr"},{"issue":"5","key":"2026082702025884900_lvag145-B16","doi-asserted-by":"publisher","first-page":"G83","DOI":"10.1093\/ejendo\/lvaf222","article-title":"Revised European Society of Endocrinology clinical practice guideline: treatment of chronic hypoparathyroidism in adults","volume":"193","author":"Bollerslev","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026082702025884900_lvag145-B17","doi-asserted-by":"publisher","first-page":"156335","DOI":"10.1016\/j.metabol.2025.156335","article-title":"Best practice recommendations for the diagnosis and management of hypoparathyroidism","volume":"171","author":"Khan","year":"2025","journal-title":"Metabolism"},{"issue":"9","key":"2026082702025884900_lvag145-B18","doi-asserted-by":"publisher","first-page":"bvaf113","DOI":"10.1210\/jendso\/bvaf113","article-title":"Switch from rhPTH1-84 to TransCon PTH with individual dose adjustment in adult hypoparathyroidism\u20144-week results","volume":"9","author":"Siggelkow","year":"2025","journal-title":"J Endocr Soc"},{"issue":"12","key":"2026082702025884900_lvag145-B19","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.eprac.2025.08.008","article-title":"Early U.S. Real-world treatment patterns and outcomes in palopegteriparatide treatment for patients with hypoparathyroidism","volume":"31","author":"Graham","year":"2025","journal-title":"Endocr Pract"},{"issue":"4","key":"2026082702025884900_lvag145-B20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1210\/clinem\/dgae693","article-title":"Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial","volume":"110","author":"Clarke","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026082702025884900_lvag145-B21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12020-020-02577-x","article-title":"Chronic hypoparathyroidism and treatment with teriparatide","volume":"72","author":"Marcucci","year":"2021","journal-title":"Endocrine"},{"issue":"8):","key":"2026082702025884900_lvag145-B22","doi-asserted-by":"publisher","first-page":"e2030","DOI":"10.1210\/clinem\/dgag160","article-title":"Approach to the patient: management of bone fragility in patients with chronic hypoparathyroidism","volume":"111","author":"Tournis","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026082702025884900_lvag145-B23","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1007\/s12325-024-02843-8","article-title":"Palopegteriparatide treatment improves renal function in adults with chronic hypoparathyroidism: 1-year results from the phase 3 PaTHway trial","volume":"41","author":"Rejnmark","year":"2024","journal-title":"Adv Ther"},{"issue":"1","key":"2026082702025884900_lvag145-B24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1210\/jc.2017-01555","article-title":"PTH(1\u201334) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life","volume":"103","author":"Palermo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026082702025884900_lvag145-B25","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s40618-022-01800-y","article-title":"Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1\u201384) treatment","volume":"45","author":"Marcucci","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2026082702025884900_lvag145-B26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/cen.14813","article-title":"The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1-84): a retrospective cohort study","volume":"98","author":"Rejnmark","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026082702025884900_lvag145-B27","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/jbmr.4274","article-title":"Safety and efficacy of oral human parathyroid hormone (1-34) in hypoparathyroidism: an open-label study","volume":"36","author":"Ish-Shalom","year":"2020","journal-title":"J Bone Miner Res"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/2\/372\/70813263\/lvag145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/2\/372\/70813263\/lvag145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:03:02Z","timestamp":1787810582000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/195\/2\/372\/8771599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag145","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]}}}